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a b s t r a c t
Objectives: To evaluate the impact of new quantity limits for blood glucose test strips (BGTS) in August
2013 on utilization patterns and costs in the elderly population of Ontario, Canada.
Methods: We conducted a population-based, cross-sectional time series analysis of all individuals 65 years of
age and older who received publically funded BGTSs between August 1, 2010, and July 31, 2015, in Ontario,
Canada. The number of BGTSs dispensed and the associated costs were measured for 4 diabetes therapy
subgroups—insulin, hypoglycemia-inducing oral agents, non-hypoglycemia-inducing oral agents, and no drug
therapy—eachmonth during the study period.Weused interventional autoregressive integratedmoving average
(ARIMA) models to assess the impact of Ontario’s policy change on test strip use and costs.
Results: In the course of the study period, 657,338,177 test strips were dispensed to elderly patients in Ontario,
at a total cost of CAN$482.3 million. Introduction of quantity limits was associated with signiﬁcant reduc-
tions in the number of monthly strips dispensed and the associated costs (p<0.0001). In the year follow-
ing the policy’s implementation, test strip use decreased by 22.2% compared with the prior year (from
145,232,024 test strips to 113,007,795 test strips, a net decrease of 32,224,229 strips), resulting in a 22.5%
reduction in costs (from $106.5 million to $82.6 million, a net cost reduction of approximately $24 million).
Conclusions: The introduction of quantity limits, aligned with guidance from the Canadian Diabetes Asso-
ciation, led to immediate signiﬁcant reductions in BGTS dispensing and costs. More research is needed
to assess the impact of this policy on patient outcomes.








r é s u m é
Objectifs : Évaluer les répercussions des nouvelles restrictions quantitatives de bandelettes réactives pour
la glycémie (BRG) d’août 2013 sur les tendances et les coûts d’utilisation chez la population âgée de l’Ontario,
au Canada.
Méthodes : Nous avons mené une analyse transversale des séries chronologiques de tous les individus de 65
ans et plus qui ont reçu des BRG subventionnées par le gouvernement entre le 1er août 2010 et le 31 juillet
2015, en Ontario, au Canada. Nous avons évalué le nombre de BRG distribuées et les coûts associés de 4 sous-
groupes de traitement du diabète—insuline, agents oraux provoquant des hypoglycémies, agents oraux ne
provoquant pas d’hypoglycémies et sans pharmacothérapie—tous lesmois au cours de la période étudiée. Nous
avons utilisé desmodèles autorégressifs àmoyennesmobiles intégrés (ARMMI) pour évaluer les répercussions
des changements de politiques de l’Ontario sur l’utilisation et les coûts des bandelettes réactives.
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Résultats :Au cours de la période étudiée, 657 338 177 bandelettes réactives ont été distribuées aux patients
âgés de l’Ontario, soit un coût total de 482.3 M$ CA. La mise en place des restrictions quantitatives était
associée à des réductions signiﬁcatives du nombremensuel de bandelettes distribuées et des coûts associés
(p<0.000 1). Dans l’année qui a suivi lamise enœuvre des politiques, l’utilisation des bandelettes réactives
a diminué de 22.2% par rapport à l’année précédente (de 145 232 024 bandelettes réactives à 113 007 795
bandelettes réactives, soit une diminution nette de 32 224 229 bandelettes), ce qui a entraîné une réduction
des coûts de 22.5 % (de 106.5 M$ à 82.6 M$, soit une réduction nette approximative des coûts de 24 M$).
Conclusions : La mise en place des restrictions quantitatives, en conformité avec l’Association canadienne
du diabète, a entraîné des réductions signiﬁcatives immédiates dans la distribution des BRG et des coûts
qui y sont associés. D’autres recherches sont nécessaires pour évaluer les répercussions de cette politique
sur les résultats cliniques des patients.
© 2016 Canadian Diabetes Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The optimal use of self-monitoring of blood glucose (SMBG) by
people with diabetes is an area of uncertainty, given the need to
balance appropriate use affecting patient care and the potential for
overuse and unnecessary healthcare costs (1–3). Indeed, a 2009
Canadian review suggested that in individuals with diabetes who
do not use insulin, frequent testing may not offer any clinical beneﬁt
and may, in fact, cause increased anxiety (4,5). Moreover, the aggre-
gate costs of blood glucose test strips (BGTSs) can represent con-
siderable cost burdens. Between 2010 and 2013, BGTSs were
consistently among the top 10 expenditures in the Ontario public
drug formulary (6–8). One approach taken by public drug insur-
ers has been the introduction of annual limits on the number of
BGTSs reimbursed. The aim of these policies is to provide patients
with suﬃcient test strips for appropriate blood glucose monitor-
ing while reducing the potential for overuse and unnecessary
expense. Studies have suggested that the ﬁnancial implications of
such limits are considerable (9,10), with 5-year savings estimated
to be approximately $100 million and $23 million in Ontario and
British Columbia, Canada, respectively (11).
Following consultation with clinical experts and stakeholders,
the Ontario public drug plan introduced quantity limits for BGTSs
in August 2013 that aligned with the guidance published by the
Canadian Diabetes Association (3,12). The policy limits reimburse-
ment to up to 3000 strips per year for insulin-treated patients, 400
strips per year for those treated with oral hypoglycemic agents
(OHAs) that may cause hypoglycemia (such as sulfonylureas), and
200 strips per year for all other individuals with diabetes. Extra test
strips are reimbursed if there is a clinical rationale for more fre-
quent testing, such as drug interactions that impact blood glucose
control, failing to meet glycemic targets for 3 or more months, or
an occupation that requires strict avoidance of hypoglycemia (13).
As other drug insurers consider policy options for addressing the
rising costs associated with BGTSs, evaluations of the impact of
Ontario’s policy on utilization, costs and outcomes are needed. We
report the ﬁndings of the ﬁrst phase of an evaluation of Ontario’s
policy; the study assessed the impact of quantity limits on test strip
utilization patterns and costs in Ontario by seniors.
Methods
We conducted a population-based, cross-sectional time series
analysis of all individuals 65 years of age and older who received
publically funded BGTSs between August 1, 2010, and July 31, 2015,
in Ontario, Canada. This study was approved by the Research Ethics
Board of Sunnybrook Health Sciences Centre, Toronto.
Cohort deﬁnition
We included all individuals 65 years of age and older who were
dispensed BGTSs reimbursed by the Ontario Public Drug Program
during the study period. Prescriptions were identiﬁed using the
Ontario Drug Beneﬁt database, which captures all reimbursedmedi-
cations dispensed at Ontario retail pharmacies to individuals eli-
gible for public drug coverage. Prescriptions with missing patient
identiﬁers or age and those dispensed to individuals younger than
65 were excluded from the analysis.
Outcome deﬁnition
Each month, we determined the number of test strips dis-
pensed to eligible patients and the associated public payer costs
(product costs and dispensing fees, excluding deductibles). Costs
were expressed in nominal Canadian dollars. Furthermore, we
created 2 cohorts of patients using BGTSs in the year prior to (July
1, 2012, to June 30, 2013) and following (August 1, 2013, to July 31,
2014) the implementation of Ontario’s policy to compare pat-
terns of utilization and costs in the prepolicy and postpolicy periods.
We excluded the month immediately prior to implementation of
the policy (July 2013) because of anomalous dispensing patterns
suggestive of stockpiling by patients in anticipation of the policy.
We allocated patients to 1 of 4 hierarchic and mutually exclusive
groups on the basis of the diabetes treatment received in each period,
as follows: those treatedwith insulin; those receiving hypoglycemia-
inducing oral glucose-lowering drugs (sulfonylureas or repaglinide);
those receiving non-hypoglycemia-inducing glucose-lowering drugs;
and those not receiving diabetes medications. The total number of
test strips dispensed, the average number of test strips dispensed
per patient, and the proportion of individuals exceeding the Ontario
quantity limits were identiﬁed and stratiﬁed by cohort (prepolicy
vs. postpolicy) and diabetes therapy group. Finally, to assess whether
patients were being prescribed insulin in order to access higher BGTS
quantity limits, we identiﬁed the total number of new insulin users
in the year prior to and following the policy’s implementation, as
well as the number of new insulin users who received only 1 pre-
scription for insulin in each time period.
Patients’ characteristics
We used the Registered Persons Database to obtain demo-
graphic characteristics of individuals dispensed BGTSs in the 1 year
prior to and following the policy’s implementation. The Canadian
Institute for Health Information’s Discharge Abstract Database was
used to determine each individual’s Charlson comorbidity index
using hospitalization data over the past 3 years.
Statistical analysis
We used a Winters additive smoothing model to forecast BGTS
utilization patterns over our 2-year follow up based on trends
observed in the 3 years prior to the policy’s implementation (exclud-
ing July 2013 due to observed stockpiling). We used interventional
autoregressive integrated moving average models to examine the
impact of Ontario’s quantity-limit policy (August 2013) on the
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number of BGTSs dispensed to the elderly in Ontario. The effects
of the policy were assessed using a step function in the model. We
assessed the autocorrelation, partial autocorrelation and inverse
autocorrelation correlograms for model parameter selection and
appropriateness, stationarity using the augmented Dickey-Fuller test
and autocorrelation using the Ljung-Box chi-square test. We used
chi-square tests to compare the proportion of individuals exceed-
ing the policy’s quantity limits between the prepolicy and postpolicy
cohorts. All analyses were performed at the Institute for Clinical
Evaluative Sciences (www.ices.on.ca) using SAS software (SAS v. 9.3
and SAS EG 6.1; SAS Institute, Cary, North Carolina, USA) and using
a type 1 error rate of 0.05 as the threshold for statistical signiﬁcance.
Results
Between August 2010 and July 2015, a total of 657,338,177 test
strips were dispensed to elderly patients in the Ontario Public Drug
Program, costing $482.3 million. In July 2013, the month prior to
the implementation of Ontario’s quantity-limit policy, BGTS utili-
zation increased by 38% to 16,672,407 test strips dispensed (costing
$12.6 million) from a monthly average of 12,075,188 test strips
(average cost $9.1 million) in the 6 months prior. Patients’ charac-
teristics and comorbidities were similar in the year prior to and fol-
lowing the policy’s implementation (Table 1). On average, BGTS users
were 75 years old, and approximately half were male.
We ﬁt an interventional autoregressive integratedmoving average
(ARIMA) model (8, 1, 0) to the data over the entire study period
(August 2010 to July 2015), with an R-square of 0.74. Using a step
function in the ARIMA model to measure the impact of Ontario’s
policy, we found a signiﬁcant, sustained reduction in the number
of test strips dispensed (p<0.0001) (Figure 1). There were 32,224,229
fewer BGTS dispensed in the year following the policy’s implemen-
tation (113,007,795 strips, August 2013 to July 2014) compared to
the prior year (145,232,024 strips, July 2012 to June 2013), result-
ing in a 1-year savings of $23.9 million (from $106.5 million to $82.6
million). By the end of the study period (July 2015), 9,262,553 test
strips were dispensed monthly to elderly drug beneﬁciaries in
Ontario at a cost of $7.0million (comparedwith 11,829,943 test strips
monthly at a cost of $8.9 million in June 2013, prior to the
policy’s implementation).
In the year following the implementation of Ontario’s policy,
several shifts in test strip utilization emerged (Table 2). For example,
the number of individuals dispensed BGTS fell among those treated
with no drug therapy and hypoglycemia-inducing OHAs and rose
among those treated with non-hypoglycemia-inducing OHAs and
insulin. Furthermore, the number of BGTSs dispensed fell 44.1% (from
Table 1
Characteristics of patients using blood glucose test strips in the 1 year preceding
and following the policy’s implementation
Characteristic 1 year prepolicy cohort
n=324,689
1 year postpolicy cohort
n=327,716
Age (mean ± SD) 74.5±7.2 74.6±7.2
Male sex (n, %) 163,279 (50.3%) 165,237 (50.4%)
Income quintile
1 70 060 (21.6%) 70 359 (21.5%)
2 70 728 (21.8%) 71 303 (21.8%)
3 65 747 (20.2%) 66 342 (20.2%)
4 62 814 (19.3%) 63 853 (19.5%)
5 53 736 (16.5%) 54 170 (16.5%)
Missing 1604 (0.5%) 1689 (0.5%)
Rural
No 280,030 (86.2%) 283,196 (86.4%)
Yes 44 271 (13.6%) 44 043 (13.4%)
Missing 388 (0.1%) 477 (0.1%)
Charlson morbidity index
No hospitalization 219,033 (67.5%) 221,258 (67.5%)
0 12 043 (3.7%) 11 814 (3.6%)
1 24 780 (7.6%) 24 560 (7.5%)
2+ 68 833 (21.2%) 70 084 (21.4%)
Figure 1. Trends in blood glucose test strip utilization and costs in Ontario: August 2010 to July 2015. Ontario policy introduced in August 2013. Elevated dispensing in July
2013 is indicative of stockpiling prior to policy implementation.
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13.1 to 7.3 million strips), 47.2% (from 33.6 to 17.7 million strips)
and 40.0% (from 34.4 to 20.7 million strips) among those treated
with no drug therapy, non-hypoglycemia-causing OHAs and
hypoglycemia-causing OHAs, respectively. In contrast, the number
of test strips dispensed to individuals treated with insulin rose 4.9%
(from 64.2 million to 67.3 million test strips). Between August 1,
2013, and July 31, 2014, 59.6% of all BGTSs were dispensed to indi-
viduals treated with insulin (compared to 44.2% in the prior year).
These trends continued into the second year following the policy
intervention, with 63.1% of BGTSs being dispensed to individuals
treated with insulin.
The average annual rate of BGTS use and costs per person
decreased across all diabetes therapy groups (Table 2). This reduc-
tion was most apparent among non-insulin treated patients, for
whom the average annual rate of BGTS use dropped by more than
100 test strips per person, and average annual costs were lowered
by between $80 and $118 per person (Table 2). Among those treated
with insulin, on average, 20 fewer test strips were dispensed annu-
ally per person following the introduction of the policy (from 748
to 728 test strips per patient, annually), leading to a minimal shift
in annual costs ($14 savings per person, from $554 to $540 per
person, annually). This led to a signiﬁcant shift in the prevalence
of individuals exceeding the quantity limits introduced by the gov-
ernment (p<0.0001) (Table 3). In the year following the policy’s intro-
duction, 6.4% of individuals receiving no diabetes drug therapy, 10.0%
of those treated with non-hypoglycemia-inducing OHAs and 5.4%
of those treated with hypoglycemia-inducing OHAs received BGTS
quantities that exceeded the policy’s limits (compared to 34.1%, 48.2%
and 31.4% in the prior year, respectively). This was even lower in
the second year following the policy’s implementation, ranging from
4.9% to 7.7%. Among those treated with insulin, only 59 patients
(0.06%) and 101 patients (0.1%) exceeded the quantity limit of 3000
BGTSs in the 1 and 2 years following the policy implementation,
respectively, compared to 273 (0.3%) in the prior year.
In our investigation of insulin use, we found that there were
slightly more individuals initiating insulin in the year following the
policy’s implementation compared to the year preceding it
(n=15 706, 4.8% prepolicy vs. n=16 206, 5.0% postpolicy; p=0.04).
Among those initiating insulin in each time period, a slightly higher
proportion received only 1 prescription in the year following the
policy’s implementation (n=2712, 16.7%) compared with the year
preceding policy implementation (n=2382, 15.2%; p=0.0001).
However, these shifts did not persist into the second year follow-
ing the policy’s implementation (p=0.93 and p=0.06, respectively).
Discussion
In this large, population-based study, we found that the intro-
duction of a policy designed to restrict the quantity of BGTSs dis-
pensed to elderly individuals with diabetes in a way that aligned
with clinical guidance led to a considerable and sustained shift in
the dispensing patterns of these products. Speciﬁcally, the policy
led to almost $24 million in savings over the subsequent year, with
the majority of the decreased use occurring among those individu-
als with diabetes not treated with insulin.
Our ﬁndings regarding shifts in diabetes therapy groups after the
policy implementation warrant further discussion. In particular, we
Table 2
Blood glucose test strip utilization among prepolicy and postpolicy test strip users, by diabetes therapy group


















Overall 324,689 1,075,665 145,232,024 3.3 (2.9) 447 (426) $328 ($317)
No drug therapy 50 873 (15.7%) 107,768 (10.0%) 13,056,735 (9.0%) 2.1 (1.8) 257 (255) $182 ($190)
Non-hypoglycemia-causing OHAs 102,935 (31.7%) 269,170 (25.0%) 33,554,480 (23.1%) 2.6 (2.2) 326 (290) $237 ($217)
Hypoglycemia-causing OHAs 85 081 (26.2%) 265,617 (24.7%) 34,423,490 (23.7%) 3.1 (2.5) 405 (347) $298 ($360)
Insulin 85 800 (26.4%) 433,110 (40.3%) 64,197,319 (44.2%) 5.1 (3.6) 748 (544) $554 ($401)
Year 1 postpolicy
Overall 327,716 875,465 113,007,795 2.7 (2.6) 345 (380) $252 ($283)
No drug therapy 48 723 (14.9%) 69 127 (7.9%) 7,302,103 (6.5%) 1.4 (0.6) 150 (68) $102 ($54)
Non-hypoglycemia-causing OHAs 105,469 (32.2%) 164,439 (18.8%) 17,724,002 (15.7%) 1.6 (0.7) 168 (70) $119 ($55)
Hypoglycemia-causing OHAs 81 001 (24.7%) 180,196 (20.6%) 20,665,543 (18.3%) 2.2 (1.2) 255 (132) $187 ($99)
Insulin 92 523 (28.2%) 461,703 (52.7%) 67,316,147 (59.6%) 5.0 (3.7) 728 (528) $540 ($390)
Year 2 postpolicy
Overall 328,870 886,942 112,469,184 2.7 (2.7) 342 (392) $252 ($292)
No drug therapy 46 291 (14.1%) 62 815 (7.1%) 6,492,722 (5.8%) 1.4 (0.6) 140 (67) $98 (54)
Non-hypoglycemia-causing OHAs 106,019 (32.2%) 157,923 (17.8%) 16,558,652 (14.7%) 1.5 (0.7) 156 (69) $113 (54)
Hypoglycemia-causing OHAs 78 344 (23.8%) 168,812 (19.0%) 18,494,009 (16.4%) 2.2 (1.2) 236 (130) $174 (98)
Insulin 98 216 (29.9%) 497,392 (56.1%) 70,923,801 (63.1%) 5.1 (3.8) 722 (533) $537 (394)
OHA, oral hypoglycemic agents.
Table 3
Prevalence of patients exceeding blood glucose test strip quantity limits pre- and postpolicy, by diabetes therapy group













n % n % n %
No drug therapy 50 873 17 356 34.1% 48 723 3128 6.4% <.0001 46 291 2290 5.0% <.0001
Non-hypoglycemia-causing OHA 102,935 49 600 48.2% 105,469 10 584 10.0% <.0001 106,019 8186 7.7% <.0001
Hypoglycemia-causing OHA 85 081 26 685 31.4% 81 001 4390 5.4% <.0001 78 344 3820 4.9% <.0001
Insulin 85 800 273 0.3% 92 523 59 0.1% <.0001 98 216 101 0.1% <.0001
OHA, oral hypoglycemic agents.
a Chi-square test of proportions for prepolicy vs. year 1 postpolicy.
b Chi-square test of proportions for prepolicy vs. year 2 postpolicy.
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found that fewer people were treated with hypoglycemia-inducing
OHAs, while more were treated with insulin. Furthermore, there was
a signiﬁcantly increased prevalence of individuals receiving just 1
prescription for insulin in the year following the policy implemen-
tation; however, this did not persist into the second year of follow
up. Although these patterns suggest that prescribers may have
shifted their patterns of diabetes therapy prescribing to subvert
quantity limits for BGTSs, overall this represented a small number
of patients (330 additional new insulin users who were dispensed
only 1 insulin prescription).
Following Ontario’s implementation of quantity limits in 2013,
several other public drug funders have followed suit, including both
British Columbia’s provincial drug program andHealth Canada’s Non-
Insured Health Beneﬁts Program (14,15). This study provides useful
information for other jurisdictions regarding the potential cost
savings that might be realized following the introduction of these
policies (~22% lower costs in year after vs. year prior to policy). Fur-
thermore, other drug programs considering similar policies should
take note of our ﬁndings of increased BGTS dispensing in the month
prior to the policy implementation because it is likely that this
increased dispensing activity will occur elsewhere in the time
between the announcement of a policy of restricted access and full
policy implementation.
This study has many strengths, including its population-based
design and long study period (including 2 years of follow up after
the implementation of the quantity-limit policy). However, several
limitations merit emphasis. First, we cannot measure the impact of
the escalated BGTS dispensing in the month prior to policy imple-
mentation on subsequent BGTS needs in the following year. As a result,
it is possible that some individuals were testingmore frequently than
suggested by their subsequent prescription claims, given their accu-
mulation of BGTS prior to the policy’s implementation. However, we
did not observe an increase in BGTS dispensing in the second year
following the quantity-limit policy’s implementation, suggesting that
the observed reductions in utilization and costs can be expected to
be maintained in the future. Second, we do not have access to pre-
scriptions paid for through private drug insurers or cash. Therefore,
it is possible that some individuals were supplementing their access
to BGTSs through other means. Third, it is likely that many of those
individuals identiﬁed as having exceeded the quantity limits
postpolicy in Table 3 met the policy’s criteria for extra test strips.
However, we were unable to determine whether these individuals
trulymet these conditions (i.e. drug interactions, occupational hazards)
due to limitations in our data and so cannot determine whether this
additional use was appropriate. Finally, we do not know whether
reduced access to BGTSs has led to changes in clinical outcomes for
those impacted by this policy in Ontario. Future research is needed
to assess these outcomes once data becomes available.
Conclusions
This large, population-based analysis suggests that the implemen-
tation of an SMBG quantity limit policy that aligns with current evi-
dence can lead to considerable cost savings and that exceptions to these
limits occur in less than 10% of the population. As more data become
available concerning clinical outcomes, studies are needed to evalu-
ate the impact of BGTS quantity limits on patients’ outcomes.
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